Immune Pharma's stock rockets on heavy volume after license pact

Shares of Immune Pharmaceuticals Inc. rocketed 75% in active premarket trade Thursday, after the biopharmaceutical company announced a license agreement with Pint Pharma to commercialize Immune's cancer treatment Ceplene in Latin America. Volume spiked to over 700,000 shares 30 minutes before the open, already more than four-times the full-day regular-session average of about 166,000 shares. As part of the agreement, Pint will make a $4 million investment in Immunue's oncology subsidiary...